Company profile: Caris Life Sciences
1.1 - Company Overview
Company description
- Provider of molecular profiling and AI-driven precision oncology solutions, offering tissue-based profiling, specimen testing services to identify molecular cancer characteristics for personalized treatment, shipper kits for specimen transport, and billing services.
Products and services
- Molecular Profiling: Bioinformatics-based product that interrogates biological markers in the genome and proteome to elucidate disease at a molecular level, enabling precision medicine in oncology
- Testing Services: Oncology-focused services that test specimens to identify molecular characteristics of cancer for tailored treatment decisions, delivering results to inform personalized therapy selection
- Tissue-based Profiling: Tissue-sample-based system that examines tissue samples to identify cancer characteristics for personalized treatment plans, producing detailed profiles to guide individualized clinical decision-making
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Caris Life Sciences
ElevateBio
HQ: United States
Website
- Description: Provider of cell and gene-based therapy solutions, offering cGMP manufacturing and process development through BaseCamp; gene-editing capabilities with Life Edit; integrated technology platforms spanning gene editing, cell therapy enabling technologies, RNA engineering, and delivery; and development of in vivo and ex vivo therapeutic programs leveraging internal R&D and partnerships.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ElevateBio company profile →
Life Genomics
HQ: Sweden
Website
- Description: Provider of genetic testing services for healthcare and the public; founded in 2014 as a spin-off from TATAA Biocenter, operating a shared laboratory with TATAA, one of Europe’s premier, with backing including government ALMI Invest.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Life Genomics company profile →
Strata Oncology
HQ: United States
Website
- Description: Provider of precision oncology solutions, including Strata Select, a DNA/RNA-based molecular profiling test guiding immunotherapy and other treatment selection for advanced cancer; the Immunotherapy Response Score predicting benefit of anti-PD-1/PD-L1 monotherapy; and clinical trials such as Strata PATH and Strata Trial enabling biomarker-guided evaluation and access to approved and investigational therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Strata Oncology company profile →
Transgenomic
HQ: United States
Website
- Description: Provider of nucleic acid purification and analysis products for life sciences research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Transgenomic company profile →
Corlieve Therapeutics
HQ: France
Website
- Description: Provider of novel therapeutic options for patients with severe neurological disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Corlieve Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Caris Life Sciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Caris Life Sciences
2.2 - Growth funds investing in similar companies to Caris Life Sciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Caris Life Sciences
4.2 - Public trading comparable groups for Caris Life Sciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →